Sort by
Refine Your Search
-
Listed
-
Country
-
Program
-
Field
-
and disease risk factors Investigate new approaches in the analysis of large neurophysiological datasets We are seeking a highly motivated candidate with: A strong master’s degree in psychology
-
, for enhancing light trapping in nanostructured thin-film solar cells. Your role will focus on developing and applying large-scale electromagnetic simulations to identify optimal nanostructured light-trapping
-
Postdoc "Interferometric SAR Data Processing and Analysis for Implementation in the 3D-ABC Founda...
products from the TanDEM-X radar mission, large airborne and field-based LiDAR datasets, and process-based models, as well as other openly available remote sensing and field datasets. The diverse data will
-
Organization (RTO) active in the fields of materials, environment and IT. By transforming scientific knowledge into technologies, smart data and tools, LIST empowers citizens in their choices, public authorities
-
interdisciplinary team at the Technische Universität Dresden, focusing on the integration of multi-omics data to better understand, diagnose, and treat metabolic diseases (i.e. obesity, diabetes, metabolic
-
Postdoctoral Fellowship in AI and Large Language Models for Transforming Pediatric Healthcare The Computational Health Informatics Program (CHIP) at Boston Children's Hospital, affiliated with
-
analysis of biomedical data and bioscientific programming for a project on the study of neurological disorders. The candidate should have experience in the analysis of large-scale biomedical data (e.g
-
extraction, sequencing library preparation, Hi-C, ATAC-seq etc.) Experience with bioinformatic analysis of large sequencing data sets Strong statistical skills using R Desirable: Experience with assembly
-
, diet, and immune system to investigate their roles in various diseases, including but not limited to cancer, metabolic disorders, and infections. The research design involves the integration of large
-
oncology grouping sees close to 550 new cases of these cancers a year. There is a large active clinical trials programme that spans phase 1 to phase 3. These patients have a poor prognosis, and this clinic